Paper Report for: Bi_2022_Bull.Exp.Biol.Med_173_346
Reference
Title: A New Berberine Preparation Protects Pancreatic Islet Cells from Apoptosis Mediated by Inhibition of Phospholipase A(2)/p38 MAPK Pathway Bi XJ, Lv YQ, Yang XH, Ge Y, Han H, Feng JS, Zhang M, Chen L, Xu MZ, Guan FY Ref: Bulletin of Experimental Biology & Medicine, 173:346, 2022 : PubMed
We studied an amorphous solid dispersion of berberine with absorption enhancer sodium caprate (Huang-Gui solid dispersion preparations, HGSD). A therapeutic effect of HGSD was revealed in mice with type 2 diabetes mellitus and palmitate-induced injury to MIN6 beta-cells. HGSD treatment (150 mg/kg) improved glucose metabolism and decreased beta-cell apoptosis in diabetic mice. Furthermore, the effective component of HGSD berberine significantly attenuated the palmitate-induced decrease in MIN6 beta-cells viability and insulin secretion. Moreover, molecular docking analysis and Western blotting showed that berberine decreased cell apoptosis and expression of group VIA phospholipase A(2) (iPLA(2)), p38 mitogen-activated protein kinase (p38 MAPK), and caspase-3. These data suggest that HGSD treatment protected beta-cells via inhibiting the iPLA(2)/p38 MAPK pathway.
        
Related information
Citations formats
Bi XJ, Lv YQ, Yang XH, Ge Y, Han H, Feng JS, Zhang M, Chen L, Xu MZ, Guan FY (2022) A New Berberine Preparation Protects Pancreatic Islet Cells from Apoptosis Mediated by Inhibition of Phospholipase A(2)/p38 MAPK Pathway Bulletin of Experimental Biology & Medicine173: 346-353
Bi XJ, Lv YQ, Yang XH, Ge Y, Han H, Feng JS, Zhang M, Chen L, Xu MZ, Guan FY (2022) Bulletin of Experimental Biology & Medicine173: 346-353